856676-23-8

856676-23-8结构式

中文名	非诺贝特酸胆碱盐
英文名	2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
中文别名	胆碱非诺贝特
英文别名	Choline fenofibrate UNII-4BMH7IZT98 fenofibric acid choline salt ABT-335 Fenofibrate de choline

描述	Choline Fenofibrate (ABT-335)是fenofibric acid的胆碱盐,可与rosuvastatin结合作用于血脂异常。
相关类别	信号通路 >> 代谢酶/蛋白酶 >> 细胞色素P450 研究领域 >> 心血管疾病
参考文献	[1]. Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34. [2]. Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203. [3]. Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71. [4]. Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22. [5]. Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.

600-00-0

42019-78-3

123-41-1

~70%

856676-23-8

文献：US2008/275270 A1, ; Page/Page column 3 ;

42017-89-0

67-48-1

~75%

856676-23-8

文献：WO2010/86700 A2, ; Page/Page column 7 ;

51368-55-9

42019-78-3

123-41-1

~68%

856676-23-8

文献：US2008/275270 A1, ; Page/Page column 3 ;